Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

Core Insights - Pliant Therapeutics, Inc. is participating in the Piper Sandler 37th Annual Healthcare Conference from December 2 to 4, 2025 [1] - Key executives including Bernard Coulie, M.D., Ph.D., Keith Cummings, M.D., and Éric Lefebvre, M.D. will engage in a fireside chat on December 4, 2025, at 12:30 p.m. Eastern Time [2] - A live webcast of the fireside chat will be available, with a replay archived for 90 days on Pliant's website [3] Company Overview - Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on integrin-based therapeutics [4] - The lead program, PLN-101095, is a small molecule dual-selective inhibitor targeting αvß8 and αvß1 integrins for solid tumor treatment [4] - Pliant has regulatory clearance for a Phase 1 study of PLN-101325, a monoclonal antibody agonist targeting integrin α7β1 for muscular dystrophies [4] - The company is also engaged in preclinical research on tissue-specific delivery and internalization of drug payloads using integrin receptor-binding molecules [4]